Millennium Pharmaceuticals Limited

Sean J Harrison

Shomir Ghosh

Kenneth Gordon Carson

Amy M Elder

Alexandra E Gould

Kevin Sprott

Christelle C Renou

Dominic J Reynolds

He Xu

Kenneth M Gigstad

Christopher Blackburn

Paul D Greenspan

Dylan Bradley England

Frederick A Hicks

David P Cardin

Emily Frances Calderwood

Jeremy D Little

Shih-Chung Huang

Liting Ma

Benjamin Stone Amidon

Sharmila Adhikari

Disclosed are chemical entities which are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein R, R, and Rhave the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer. 

ATG7 inhibitors and the uses thereof

Disclosed are chemical entities that inhibit Uba6, each of which is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R*is &#x2014;H or &#x2014;CH; and Y is Formula (II) or Formula (III), wherein Ris &#x2014;H, &#x2014;CHor Calkyloxycarbonyl; and R, Rand Rare defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.

Indole substituted pyrrolopyrimidinyl inhibitors of Uba6

This invention provides compounds of formula (I): 

Substituted hydroxamic acids and uses thereof

Disclosed are CRTH2 inhibitors represented by Structural Formula (I): The values for the variables of Structural Formula (I) are provided herein.

PGD2 receptor antagonists for the treatment of inflammatory diseases

Disclosed herein are compounds represented by Structural Formula (I) and (I-A):  Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply 'CRTH2' for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

Disclosed herein are compounds represented by Structural Formula (I):  Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2 ('CRTH2') for the treatment of inflammatory disorders.

Growing community of inventors

Belmont, MA, United States of America

Sean J Harrison